筛查对黑色素瘤发病率和活检率的影响
筛查组黑色素瘤风险较高(aHR 1.29),主要归因于原位黑色素瘤(aHR 1.45),侵袭性黑色素瘤无显著差异(aHR 1.05),活检率也更高(aHR 1.85),提示过度诊断。
要点
- 筛查组黑色素瘤发病率高于未筛查组(aHR 1.29,95% CI 1.02-1.63)。
- 筛查组原位黑色素瘤风险升高(aHR 1.45),侵袭性黑色素瘤无显著差异(aHR 1.05)。
- 筛查组后续活检率更高(aHR 1.85,95% CI 1.69-2.04),提示过度诊断。
核心结论
- 接受皮肤筛查者后续活检率和黑色素瘤(尤其是原位黑色素瘤)发生率更高,即使调整所有已知危险因素后仍存在,符合过度诊断。
研究设计与样本
- 从澳大利亚昆士兰州人群登记中随机选取43762名40-69岁无黑色素瘤史居民,2010年基线调查皮肤筛查史,随访第2-7年通过癌症登记获取黑色素瘤发病率,第2-6年获取活检率,采用倾向评分分析计算调整风险比(aHR)和95%置信区间(CI)。
主要发现
- 28155名参与者在基线前接受过皮肤筛查;随访197191人年中观察到967例首次黑色素瘤(381例侵袭性)。
- 筛查组较未筛查组黑色素瘤发病率更高(aHR 1.29,95% CI 1.02-1.63),活检率更高(aHR 1.85,95% CI 1.69-2.04)。
- 筛查组原位黑色素瘤风险更高(aHR 1.45,95% CI 1.09-1.92),侵袭性黑色素瘤无显著差异(aHR 1.05,95% CI 0.72-1.54)。
- 以基线后第一年活检定义筛查的二次分析中,活检组较未活检组黑色素瘤风险更高(aHR 1.53,95% CI 1.23-1.89),后续活检风险更高(aHR 2.64,95% CI 2.46-2.84)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous melanomas are common cancers in white-skinned populations, and early detection is promoted as a means of reducing morbidity and mortality. There is concern that increased skin screening is leading to overdiagnosis of indolent melanomas with low risk of lethality. The extent of melanoma overdiagnosis associated with screening is unknown. OBJECTIVES: To estimate possible overdiagnosis by comparing subsequent melanoma incidence and biopsy rates among people subjected to skin screening those who were not. METHODS: We recruited 43 762 residents of Queensland, Australia, aged 40-69 years, with no prior history of melanoma, selected at random from a population register in 2010. At baseline, participants completed a comprehensive melanoma risk factor survey and were asked if their skin had been examined by a doctor in the 3 years prior to baseline. We calculated incidence and relative risk of histologically confirmed melanoma (invasive and in situ) in years 2-7 of follow-up, obtained through linkage to the cancer registry. In secondary analyses, we measured biopsy rates in years 2-6 of follow-up. We used propensity score analysis to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). RESULTS: In total, 28 155 participants underwent skin screening prior to baseline. We observed 967 first-incident melanomas (381 invasive) during 197 191 person-years of follow-up. Those screened had higher rates of melanoma (aHR 1·29, 95% CI 1·02-1·63) and subsequent skin biopses (aHR 1·85, 95% CI 1·69-2·04) than unscreened participants. The higher risk associated with skin screening was evident for in situ melanoma (aHR 1·45, 95% CI 1·09-1·92) but not invasive melanoma (aHR 1·05, 95% CI 0·72-1·54). In secondary analyses, where screening was defined as having a skin biopsy in the first year after baseline, we observed significantly increased risks of melanoma (aHR 1·53, 95% CI 1·23-1·89) and subsequent biopsies (aHR 2·64, 95% CI 2·46-2·84) relative to those who did not have a biopsy. CONCLUSIONS: People who undergo skin screening subsequently experience higher rates of biopsies and melanoma (especially in situ melanoma), even after adjusting for all known risk factors, consistent with overdiagnosis. What is already known about this topic? Cutaneous melanomas are common cancers in white-skinned populations for which early detection is promoted as a means of reducing morbidity and mortality. There is concern that increased surveillance is leading to the overdiagnosis of indolent melanomas that are not destined to be lethal. The extent of melanoma overdiagnosis associated with surveillance is not known. What does this study add? People subjected to skin examinations by a doctor or who undergo skin biopsies subsequently have higher numbers of biopsies and higher rates of melanoma than people not subjected to either, even after adjusting for all known risk factors. These findings suggest that heightened surveillance leads to a proportion of melanomas being diagnosed that otherwise may not have come to clinical attention.
引用
- Whiteman DC, Olsen CM, MacGregor S, et al. The effect of screening on melanoma incidence and biopsy rates. Br J Dermatol. 2022. PMID: 35531668. doi:10.1111/bjd.21649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。